| 3.005 0.055 (1.86%) | 10-04 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.67 | 1-year : | 5.43 |
| Resists | First : | 4 | Second : | 4.65 |
| Pivot price | 3.48 |
|||
| Supports | First : | 2.95 | Second : | 2.45 |
| MAs | MA(5) : | 3.19 |
MA(20) : | 3.51 |
| MA(100) : | 6.73 |
MA(250) : | 9.54 |
|
| MACD | MACD : | -0.6  |
Signal : | -0.6 |
| %K %D | K(14,3) : | 1.9 |
D(3) : | 5.8 |
| RSI | RSI(14): 22.3 |
|||
| 52-week | High : | 44.5 | Low : | 2.95 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MTNB ] has closed above bottom band by 2.7%. Bollinger Bands are 36.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.08 - 3.1 | 3.1 - 3.12 |
| Low: | 2.91 - 2.94 | 2.94 - 2.96 |
| Close: | 2.97 - 3.01 | 3.01 - 3.04 |
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Wed, 02 Oct 2024
MTNB stock touches 52-week low at $3.24 amid market challenges - Investing.com
Tue, 03 Sep 2024
Matinas BioPharma implements reverse stock split - Investing.com
Wed, 28 Aug 2024
Matinas BioPharma enacts reverse stock split - Investing.com
Thu, 15 Aug 2024
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q2 2024 Earnings Call Transcript - Insider Monkey
Wed, 14 Aug 2024
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update - Yahoo Finance
Wed, 07 Aug 2024
Matinas BioPharma to Webcast Conference Call to Discuss - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 15.7 (%) |
| Shares Short | 58 (K) |
| Shares Short P.Month | 27 (K) |
| EPS | -5.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.8 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -50.9 % |
| Return on Equity (ttm) | -97.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.55 |
| PEG Ratio | 0 |
| Price to Book value | 0.78 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|